Revivent System for Heart Failure Treatment

RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial

Recruiting N/A Interventional Study
Left Ventricle Remodeling Left Ventricle Dilated CHF
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
135 (estimated)
Sponsor
BioVentrix · Industry
Who this trial is looking for

This trial is looking for adults with heart failure and specific heart conditions. Participants will try a new treatment alongside standard therapy and attend follow-up visits.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 18 years old or older
  • I have heart failure symptoms not relieved by medical therapy
  • I have a non-calcified scar in my heart
  • I have a Left Ventricular Ejection Fraction less than 40%
  • I have completed a 6 Minute Walk Test
  • I am on adequate heart failure medication
  • I agree to follow-up visits
  • I can give written consent

You may not be able to join if

  • I have had a heart attack in the past 90 days
  • I have severe heart valve disease
  • I need heart surgery or intervention
  • I have severe lung disease
  • I have chronic kidney failure with a GFR less than 30
  • I have had a stroke or brain bleed in the last six months
  • I am currently in another clinical trial
  • I have an active cancer that is not in remission

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary safety endpoint will be evaluated at 30 days. Primary efficacy endpoint will be at 1 year. Interim …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. 18 years old or older 2. LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and/or dyskinetic) non-calcified scar 3. LV Aneurysm/Scar Location: Defined as a scar involving anterior, apical or anterolateral ± septal regions of the left ven…
Contacts

Steve Chartier

(925) 830-1000

schartier@bioventrix.com

CONTACT